Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials DOI Creative Commons

Meng-Qun Cheng,

Rong Li,

Xin Luo

et al.

Heliyon, Journal Year: 2023, Volume and Issue: 9(12), P. e22858 - e22858

Published: Nov. 28, 2023

The benefits and risks of adjuvant-associated COVID-19 vaccines (ACVs) are unclear. study aimed to assess the immunogenicity safety ACVs compared with controls (placebo or same vaccine without adjuvants [NACVs]).Randomized controlled trials sourced from PubMed, EMBASE, Web Science, Cochrane Library were systematically reviewed. Evaluators extracted information independently. evidence quality was assessed using random-effects models. risk bias Risk Bias tool.Of 33 studies, 27 analyzed (n = 9069, group; n 3757, control), 26 58669, groups; 30733 control). Compared controls, full vaccination produced significant immune responses (relative [RR] seroneutralization reaction, 12.3; 95 % confidence interval [95 CI], 6.92-21.89; standardized mean deviation geometric titer 3.96, CI, 3.35-4.58). Additionally, immunoreactivity NACVs only (P < 0.05). Furthermore, significantly increased local systemic adverse reactions (AEs) controls. However, did not increase localized AEs > It observed that had a lower all-cause mortality than (RR, 0.51; CI 0.30-0.87). further found nAb response against all sublines Omicron variant, but antibody titers those for SARS-CoV-2 original strain.The findings this meta-analysis demonstrate may have superior effect an acceptable in preventing COVID-19. Although these results suggest potential ACVs, studies required.

Language: Английский

A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations DOI Creative Commons
Qian Gui,

Cuige Gao,

Miaomiao Zhang

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(6), P. 579 - 579

Published: May 25, 2024

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in COVID-19 pandemic, has profoundly impacted global healthcare systems and trajectory economic advancement. As nations grapple with far-reaching consequences this unprecedented health crisis, administration vaccines proven to be a pivotal strategy managing crisis. Protein-based have garnered significant attention owing their commendable safety profile precise immune targeting advantages. Nonetheless, unpredictable mutations widespread transmission SARS-CoV-2 posed challenges for vaccine developers governments worldwide. Monovalent multivalent represent two strategies development, ongoing controversy surrounding efficacy. This review concentrates on development protein-based vaccines, specifically addressing transition from monovalent formulations, synthesizes data manufacturers, antigen composition, clinical study findings, other features that shape distinct profiles overall effectiveness. Our hypothesis is could offer enhanced capability broad-spectrum protection.

Language: Английский

Citations

4
Subunit protein-based vaccines DOI
Vasso Apostolopoulos, Vivek P. Chavda

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 51 - 62

Published: Jan. 1, 2024

Language: Английский

Citations

1
Efficacy and limitations of repurposed drugs and vaccines for COVID-19 DOI Creative Commons
Nensina Murmu, Mrinmoy Sarkar,

Sananda Dey

et al.

Journal of Medicine Surgery and Public Health, Journal Year: 2023, Volume and Issue: 2, P. 100041 - 100041

Published: Dec. 26, 2023

COVID-19 is a contagious, severe acute respiratory disease caused by the coronavirus named SARS-CoV-2. In this review, we have updated nature and evolution of SARS-CoV-2 from earlier coronaviruses, highlighting rate mutation pathogenicity virus over time. The long-term pathophysiological consequences due to application limitations repurposing previously established drugs used for treatment related symptoms been discussed efficacy newly developed vaccines against COVID-19. But these certain including post-COVID complications like tissue damage organ failure. We also summarized role natural supplements, physical exercise, yoga, adequate sleep. Additionally, possibilities using mesenchymal stem cell (MSC)-derived exosomes, in failure elaborated, however, further research on manipulating exosomes regeneration healing required.

Language: Английский

Citations

3
ANÁLISE DA EFICÁCIA E SEGURANÇA DAS VACINAS CONTRA O COVID-19 EM CRIANÇAS: UMA REVISÃO INTEGRATIVA DOI Open Access
Ana Beatriz Rodrigues Soares, Alice Pontes Nogueira Vasconcelos, S Silva

et al.

Revista de Patologia do Tocantins, Journal Year: 2024, Volume and Issue: 11(2), P. 388 - 389

Published: April 20, 2024

Introdução: A pandemia do COVID- 19 trouxe a necessidade de imunização da população, visando minimizar os efeitos doença. Apesar das crianças geralmente apresentarem quadros brandos, questionando-se o benefício vacinal, proteção contra COVID-19 nessa faixa etária é fundamental. Isso se dá devido imprevisibilidade novas variantes, além papel infantil na disseminação Por conseguinte, constata-se avaliação real efetividade e segurança vacinas disponíveis SARS-Cov-2 voltadas esse grupo. Objetivo: Este trabalho visa avaliar em crianças, fim quebrar estigmas que invalidam sua ação benefício. Metodologia: Trata-se uma revisão integrativa, observada base dados PubMed, mediante critérios inclusão exclusão preestabelecidos. Incluíram-se artigos sobre eficácia Covid-19 realizados no último ano. Excluíram-se não atendiam aos objetivos estudo. Resultados: Após análise amostra, nota-se boa taxa imunogenicidade vacinas: SCB-2019, mRNA-1273, CoronaVac, FINLAY-FR-2, FINLAY-FR-1A, BNT162b2, BBV152, NVX-CoV2373 BNT162b2. Quanto à eficácia, estudos evidenciaram pela vacinação resulta taxas anticorpos específicos mais satisfatórias. Outrossim, nos com caso índice, resposta sorológica foi demasiadamente alta grupos vacina placebo. Referente ao perfil imune, encontrou-se resultados semelhantes observados outras idades. Vale ressaltar que, mesmo diante algumas proverem cobertura todas as ainda são efetivas prevenirem graves evitarem hospitalizações, como por exemplo Síndrome Multissistêmica Inflamatória Criança (MIS-C). segurança, relacionada aparecimento adversos após vacinação, revelou-se predominância manifestações leves moderadas, maior incidência reações locais, predominando dor sítio injeção, qual atenuou partir segunda dose, resolução poucos dias. Ademais, sistêmicas, fadiga, cefaleia febre, eram infrequentes. Ocorreram raros casos miocardite, pericardite, apresentando curso clínico leve benigno, sem evidências Guillain- Barré, eventos tromboembólicos, óbitos, dentre outros. Conclusão: Portanto, conjunto desses evidencia avaliadas neste estudo consideradas seguras, imunogênicas eficazes pelos predefinidos. Ressalta-se, assim, levantamento científico encontrado contradiz existentes relacionados vacina, sendo suma importância findando-se evitar doença seus agravos.

Citations

0
Harnessing Antiviral Peptides as Means for SARS-CoV-2 Control DOI Creative Commons
Khatereh Zarkesh, Mohsen Akbarian, Lobat Tayebi

et al.

COVID, Journal Year: 2023, Volume and Issue: 3(7), P. 975 - 986

Published: June 29, 2023

Several times during the past two decades, epidemic viral diseases created global challenges. Although many solutions have been proposed to deal with this tight spot, it is still believed that public vaccination represents most effective strategy handle it. So far, various kinds of vaccines including protein subunits, virus-like particles, inactivated, live attenuated, vectors, RNA, and DNA used in prevention COVID-19. Among categories vaccines, peptide a new hope for quick trustworthy access due development proteomics equipment. This review specifically focuses on therapies severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We consider here efficacy safety subunit synthetic peptides vaccine clinical trial phases. Furthermore, monoclonal antibodies ability suppress SARS-CoV-2, those candidates entered into trials until March 2023, were selected evaluated.

Language: Английский

Citations

1
Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials DOI Creative Commons

Meng-Qun Cheng,

Rong Li,

Xin Luo

et al.

Heliyon, Journal Year: 2023, Volume and Issue: 9(12), P. e22858 - e22858

Published: Nov. 28, 2023

The benefits and risks of adjuvant-associated COVID-19 vaccines (ACVs) are unclear. study aimed to assess the immunogenicity safety ACVs compared with controls (placebo or same vaccine without adjuvants [NACVs]).Randomized controlled trials sourced from PubMed, EMBASE, Web Science, Cochrane Library were systematically reviewed. Evaluators extracted information independently. evidence quality was assessed using random-effects models. risk bias Risk Bias tool.Of 33 studies, 27 analyzed (n = 9069, group; n 3757, control), 26 58669, groups; 30733 control). Compared controls, full vaccination produced significant immune responses (relative [RR] seroneutralization reaction, 12.3; 95 % confidence interval [95 CI], 6.92-21.89; standardized mean deviation geometric titer 3.96, CI, 3.35-4.58). Additionally, immunoreactivity NACVs only (P < 0.05). Furthermore, significantly increased local systemic adverse reactions (AEs) controls. However, did not increase localized AEs > It observed that had a lower all-cause mortality than (RR, 0.51; CI 0.30-0.87). further found nAb response against all sublines Omicron variant, but antibody titers those for SARS-CoV-2 original strain.The findings this meta-analysis demonstrate may have superior effect an acceptable in preventing COVID-19. Although these results suggest potential ACVs, studies required.

Language: Английский

Citations

0